Evidence map›Paper›PMID 40369519›Full record

ArticleJournal of nanobiotechnology2025

Visualization of HSP70-regulated mild-photothermal therapy for synergistic tumor treatment: a precise space-time mild-temperature photothermal ablation strategy.

Binyue Zhang, Yanchun Ma, Qi Liu, Shutong Wu, Lin Chen, Chunmei Jiang, Haonan Chen, Hongyan Jia, Ziliang Zheng, Ruiping Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Binyue Zhang *Laboratory of Molecular Imaging, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, 030000, China.
Yanchun Ma *Translational Medicine Research Center, Department of Pathology, Shanxi Medical University, Taiyuan, 030001, China.
Qi Liu *Laboratory of Molecular Imaging, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, 030000, China.
Shutong WuLaboratory of Molecular Imaging, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, 030000, China.
Lin ChenLaboratory of Molecular Imaging, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, 030000, China.
Chunmei JiangLaboratory of Molecular Imaging, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, 030000, China.
Haonan ChenLaboratory of Molecular Imaging, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, 030000, China.
Hongyan JiaDepartment of Breast Surgery, First Hospital of Shanxi Medical University, Taiyuan, 030000, China. swallow_jhy@163.com.
Ziliang ZhengLaboratory of Molecular Imaging, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, 030000, China. zzlsxty@sxmu.edu.cn.
Ruiping ZhangLaboratory of Molecular Imaging, Fifth Hospital of Shanxi Medical University (Shanxi Provincial People's Hospital), Taiyuan, 030000, China. zrp_7142@sxmu.edu.cn.

Funding

Central Guiding Local Science and Technology Development Fund Projects YDZJSX20231A054China Postdoctoral Science Foundation 2023M732142Key Laboratory of Nano-imaging and Drug-loaded Preparation of Shanxi Province 202104010910010Key Research and Development Program Project of Shanxi Province 202302130501015Open Fund from Key Laboratory of Cellular Physiology (Shanxi Medical University), Ministry of Education, China CPOF202215Shanxi Province Higher Education "Billion Project "Science and Technology Guidance Project BYJL053Shanxi Province Science Foundation for Youths 201901D211343the National Key R&D Program of China 2023YFC3402800the National Natural Science Foundation of China 82120108016the National Natural Science Foundation of China 82372028
6 · The paper itself

Abstract

Mild-temperature photothermal therapy (MPTT) advances anticancer management by regulating reactive oxygen species (ROS) and lipid peroxides (LPO) to inhibit the overexpression of heat shock protein 70 (HSP70), thus decreasing the cellular heat resistance and increasing the efficacy of tumor ablation. However, formidable challenge remains on the traditional MPTT without imaging-guided optimal treatment time point, thus inadequate HSP70 blockage would potentially further diminish the effectiveness of MPTT. Herein, a novel biomimetic nanoprobe (Cu-ABTS@CCMs) is developed, based on encapsulating the multifunctional Cu nanoparticles and ROS-responsive 2,2'-azino-bis (3-ethylbenzothiazole-6- sulphonic acid) (ABTS) within cancer cell membranes (CCMs) to ensure second near-infrared photoacoustic (NIR-II PA) imaging-guided precise MPTT time point. The core Cu nanoparticles achieve highly effective HSP70 blockage via a nearly simultaneous cascade of photocatalytic O

Indexed as

HSP70 Heat-Shock ProteinsNeoplasmsPhotothermal TherapyAnimalsBenzothiazolesCell Line, TumorCopperFemaleHumansMetal NanoparticlesMiceMice, NudePhotoacoustic TechniquesReactive Oxygen SpeciesSulfonic Acids2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acidBenzothiazolesCopperHSP70 Heat-Shock ProteinsReactive Oxygen SpeciesSulfonic AcidsBreast cancerDual-modal imagingMild-photothermal therapyRatiometric photoacoustic imagingSecond near-infrared window

Identifiers

PMID40369519
PMCPMC12076834

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.